Polymyxin BThird Party Manufacturing in India

Polymyxin B works by binding to phospholipids in the cytoplasmic membrane of Gram-negative bacteria, altering cell permeability. It disrupts the osmotic stability of the cell membrane to help the body destroy resilient bacterial pathogens via cell leakage. Unlike standard beta-lactams, it acts directly on existing lipopolysaccharide elements, bypassing common enzymatic resistance channels. It is highly effective and well-tolerated under strict medical surveillance.

Therapeutic Uses

• Multidrug-Resistant Infections: Targets severe clinical infections caused by Pseudomonas aeruginosa.
• Meningitis: Treats deep central nervous system infections sensitive only to polymyxin classes.
• Complicated Urinary Tract Infections: Eradicates deep-seated urinary pathogens resistant to conventional antibiotics.

Why Manufacturers Choose Polymyxin B

With the rise of superbugs, Polymyxin B has emerged as a crucial critical care asset for institutional markets. Securing a reliable channel for Polymyxin B third party manufacturing in India allows marketing companies to cater to specialty critical care hospitals. Our production facilities are WHO-GMP certified, employing strict pyrogen and endotoxin monitoring systems to ensure that high-potency polypeptide injections remain safe for vulnerable patients.